Publications by authors named "R E Schlossman"
Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on plasma and NK cells that enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory MM. We therefore studied adding elotuzumab to PVd (elo-PVd) in relapsed/refractory MM in a multicenter phase 2 trial.
View Article and Find Full Text PDFOrthostatic hypotension (OH) is a well-recognized phenomenon occurring in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), and is associated with significant morbidity and mortality. A retrospective analysis of patients admitted for first ASCT between June 2012 and April 2014 found that 161/222 (73%) patients were diagnosed with OH during the course of ASCT, including 51 patients who were found to have OH on the day of first orthostatic vitals check. Excluding these 51 patients, 110/171 (64%) patients developed OH during the peri-transplant period, at a median of 7 days post ASCT (95% CI: 6.
View Article and Find Full Text PDFArticle Synopsis
- A phase 3 trial analyzed the impact of adding autologous stem-cell transplantation (ASCT) to a treatment regimen involving lenalidomide, bortezomib, and dexamethasone (known as RVD) in patients with newly diagnosed multiple myeloma.
- Results showed that the group receiving RVD plus ASCT had a median progression-free survival of 67.5 months, compared to 46.2 months for those receiving just RVD, indicating a significantly lower risk of disease progression or death with ASCT.
- Although progression-free survival improved with ASCT, there was no overall survival advantage, with 5-year survival rates being comparable between the two